rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Dennis N. Berman

Director

Company insider

Files Form 4 as: Director, Inhibikase Therapeutics; Executive VP, Corp Dev, Kintera.

Every Form 4 they filed

In numbers

Trades disclosed
36
Buys
1
Sells
0
Bought
$12K
Sold
$0
Companies
2
Companies where not an officer
1
First trade
17 Mar 2005
Last trade
30 Jul 2026
Last filed
31 Jul 2026

Companies traded

Where they are an officer
KinteraDirector, Officer, 10% owner · last 18 May 20061 buy · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
IKT Inhibikase TherapeuticsDirector · Biotechnology · last 30 Jul 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
30 Jul 2026filed 31 Jul 2026IKT Inhibikase TherapeuticsBiotechnologySEC FORM 4 Code M$28K21,854 at $1.26filing
30 Jul 2026filed 31 Jul 2026IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—21,854 at $0.00filing
30 Jul 2026filed 31 Jul 2026IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—21,854 at $0.00filing
30 Jul 2026filed 31 Jul 2026IKT Inhibikase TherapeuticsBiotechnologySEC FORM 4 Code M$28K21,854 at $1.26filing
26 Jun 2026filed 30 Jun 2026IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—155,000 at $0.00filing
26 Jun 2026filed 30 Jun 2026IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—155,000 at $0.00filing
30 Jun 2025filed 2 Jul 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—108,176 at $0.00filing
14 Feb 2025filed 19 Feb 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—39,620 at $0.00filing
21 Jan 2025filed 19 Feb 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—21,854 at $0.00filing
21 Jan 2025filed 19 Feb 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—3,780 at $0.00filing
21 Jan 2025filed 19 Feb 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—6,667 at $0.00filing
21 Jan 2025filed 19 Feb 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—6,667 at $0.00filing
21 Jan 2025filed 19 Feb 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—30,000 at $0.00filing
21 Jan 2025filed 22 Jan 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—21,854 at $0.00filing
21 Jan 2025filed 22 Jan 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—21,854 at $0.00filing
21 Jan 2025filed 22 Jan 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—1,138 at $0.00filing
21 Jan 2025filed 22 Jan 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—1,138 at $0.00filing
21 Jan 2025filed 22 Jan 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—3,780 at $0.00filing
21 Jan 2025filed 22 Jan 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—3,780 at $0.00filing
21 Jan 2025filed 22 Jan 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—6,667 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed1

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.